Inhibition of heme oxygenase-1 enhances anti-cancer effects of arsenic trioxide on glioma cells

[1]  M. Kwak,et al.  Targeting NRF2 signaling for cancer chemoprevention. , 2010, Toxicology and applied pharmacology.

[2]  J. Hampe,et al.  Increased proteasome subunit protein expression and proteasome activity in colon cancer relate to an enhanced activation of nuclear factor E2-related factor 2 (Nrf2) , 2009, Oncogene.

[3]  Min Young Kim,et al.  Nitric oxide activation of Keap1/Nrf2 signaling in human colon carcinoma cells , 2009, Proceedings of the National Academy of Sciences.

[4]  Daling Zhu,et al.  A Novel Combination Therapy With Arsenic Trioxide and Parthenolide Against Pancreatic Cancer Cells , 2009, Pancreas.

[5]  Xueying Sun,et al.  Arsenic trioxide induces different gene expression profiles of genes related to growth and apoptosis in glioma cells dependent on the p53 status , 2008, Molecular Biology Reports.

[6]  Se-Jin Kim,et al.  Suppression of Nrf2-driven heme oxygenase-1 enhances the chemosensitivity of lung cancer A549 cells toward cisplatin. , 2008, Lung cancer.

[7]  Xueying Sun,et al.  Intravenous Administration of Arsenic Trioxide Encapsulated in Liposomes Inhibits the Growth of C6 Gliomas in Rat Brains , 2008, Journal of chemotherapy.

[8]  A. Józkowicz,et al.  Heme oxygenase-1 in tumors: is it a false friend? , 2007, Antioxidants & redox signaling.

[9]  P. Hogg,et al.  Arsenical-based cancer drugs. , 2007, Cancer treatment reviews.

[10]  Shyam Biswal,et al.  Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. , 2007, Annual review of pharmacology and toxicology.

[11]  S. Shen,et al.  Baicalein inhibition of oxidative-stress-induced apoptosis via modulation of ERKs activation and induction of HO-1 gene expression in rat glioma cells C6. , 2006, Toxicology and applied pharmacology.

[12]  Yen-Chou Chen,et al.  Quercetin inhibition of ROS-dependent and -independent apoptosis in rat glioma C6 cells. , 2006, Toxicology.

[13]  C. B. Pickett,et al.  Nrf2 Controls Constitutive and Inducible Expression of ARE-driven Genes through a Dynamic Pathway Involving Nucleocytoplasmic Shuttling by Keap1* , 2005, Journal of Biological Chemistry.

[14]  S. Reddy,et al.  Gene expression profiling of NRF2-mediated protection against oxidative injury. , 2005, Free radical biology & medicine.

[15]  A. Carpentier.  Neuro-oncology: the growing role of chemotherapy in glioma , 2005, The Lancet Neurology.

[16]  C. B. Pickett,et al.  The pathways and molecular mechanisms regulating Nrf2 activation in response to chemical stress. , 2004, Free radical biology & medicine.

[17]  D. Wion,et al.  Development of gliomas: potential role of asymmetrical cell division of neural stem cells. , 2004, The Lancet. Oncology.

[18]  Solomon H. Snyder,et al.  Biliverdin reductase: A major physiologic cytoprotectant , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[19]  S. Kalivendi,et al.  Paradoxical effects of metalloporphyrins on doxorubicin-induced apoptosis: scavenging of reactive oxygen species versus induction of heme oxygenase-1. , 2002, Free radical biology & medicine.

[20]  Janet S. Lee,et al.  Mechanisms of action of arsenic trioxide. , 2002, Cancer research.

[21]  S. Namkoong,et al.  Down-regulation of human papillomavirus E6/E7 oncogene by arsenic trioxide in cervical carcinoma cells. , 2002, Cancer letters.

[22]  Changbin Shi,et al.  Effect of As2O3 on cell cycle progression and cyclins D1 and B1 expression in two glioblastoma cell lines differing in p53 status. , 2002, International journal of oncology.

[23]  O. Ogawa,et al.  Tumor growth inhibition by arsenic trioxide (As2O3) in the orthotopic metastasis model of androgen-independent prostate cancer. , 2001, Cancer research.

[24]  A. Choi,et al.  Carbon Monoxide Generated by Heme Oxygenase 1 Suppresses Endothelial Cell Apoptosis , 2000, The Journal of experimental medicine.

[25]  P. Pandolfi,et al.  Retinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteins. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[26]  Wei Tang,et al.  Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. , 1997, Blood.

[27]  T. Yoshimoto,et al.  Expression of heme oxygenase and inducible nitric oxide synthase mRNA in human brain tumors. , 1996, Biochemical and biophysical research communications.

[28]  Y. Kan,et al.  Induction of murine NAD(P)H:quinone oxidoreductase by 2,3,7,8-tetrachlorodibenzo-p-dioxin requires the CNC (cap 'n' collar) basic leucine zipper transcription factor Nrf2 (nuclear factor erythroid 2-related factor 2): cross-interaction between AhR (aryl hydrocarbon receptor) and Nrf2 signal transduc , 2004, The Biochemical journal.